<DOC>
	<DOCNO>NCT02300701</DOCNO>
	<brief_summary>To evaluate efficacy anti-IgE ( Omalizumab/Xolair ) child severe eczema .</brief_summary>
	<brief_title>Role Anti-IgE Severe Childhood Eczema</brief_title>
	<detailed_description>To address value anti-IgE child severe eczema .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>1 . Children age 419 year 2 . Severe eczema 3 . Raised SpIgE SPT least 1 food allergen 1 aeroallergen AND/OR 4 . Clinical impression allergic exposure cause worsen eczema . 5 . Total IgE level &gt; 300 kU/l 6 . Clinically proven IgEmediated allergic disease . 7 . Written inform consent participate . Exclusion criterion : 1 . Inability comply 24 weekly injection clinic visit 2 . Evidence underlie immune compromise , autoimmune disease , immune complex mediate condition . 3 . Uncontrolled infection unstable eczema . 4 . Malignancy history malignancy . 5 . Preexisting hepatic renal impairment 6 . Known cardiovascular ischaemic cerebrovascular abnormality . 7 . Other serious uncontrolled systemic disease . 8 . Pregnancy lactation . 9 . Known history hypersensitivity anaphylaxis antiIgE injection constituent . 10 . Insufficient understanding trial assessment . 11 . Participation CTIMP previous 60 day ( know ) 4 halflives relevant medication , whichever great . 12 . Investigator feel good clinical reason child would unsuitable .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>